Quantcast

Latest MicroRNA Stories

2014-06-16 08:28:15

- Recognized Industry Leader Brings Extensive Clinical and Product Development Expertise - LA JOLLA, Calif., June 16, 2014 /PRNewswire/ -- Regulus Therapeutics Inc. (NASDAQ:RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, announced today the appointment of Paul C. Grint, M.D. to its executive management team as Chief Medical Officer. In his new role, Dr. Grint will be responsible for leading and expanding Regulus'...

depression brain molecule
2014-06-09 04:40:57

redOrbit Staff & Wire Reports - Your Universe Online Levels of a tiny molecule known as miR-1202 are lower in the brains of people suffering from depression, suggesting that it could serve as a marker for depression and help detect which patients are most likely to respond to antidepressant treatment, experts from McGill University and the Douglas Institute claim in a new study. Their research, which has been published by the journal Nature Medicine, shows that miR-1202 could...

2014-06-04 12:29:29

THOROLD, ON, June 4, 2014 /PRNewswire/ - Norgen Biotek Corp., an innovative privately held Canadian biotechnology company focusing primarily on advancing powerful tools for nucleic acids (NA) and protein purification, today announced the launch of 6 novel kits for the fast and simple isolation of NA from blood, plasma/serum and urine, including cell-free-circulating (cfc)RNA, cfcDNA and sequential cfcDNA and cfcRNA. Data from comparisons of these kits with similar kits on the...

2014-05-26 11:13:00

UT Southwestern Medical Center A microRNA cluster believed to be important for suppressing colon cancer has been found to play a critical role in wound healing in the intestine, UT Southwestern cancer researchers have found. The findings, first discovered in mice and later reproduced in human cells, could provide a fresh avenue for investigating chronic digestive diseases and for potentially repairing damage in these and other disease or injury settings. "We identified a novel role...

2014-05-19 12:27:37

LONDON, May 19, 2014 /PRNewswire/ -- Reportbuyer.com has added a new market research report:Cancer Profiling and Pathways: Technologies and Global Marketshttp://www.reportbuyer.com/pharma_healthcare/diseases/cancer/cancer_profiling_pathways.htmlSTUDY GOALS AND OBJECTIVESThis BCC Research report, BIO073B: Cancer Profiling and Pathways: Technologies and Global Markets, provides a detailed overview and thorough analysis and insight of the present and future cancer profiling and...

2014-05-19 10:21:58

University of Cincinnati Academic Health Center About one in seven men will develop prostate cancer over the course of a lifetime, and about one in 36 men will die from it. This is why findings by Cincinnati Cancer Center researchers, showing that a tumor suppressive microRNA, when activated by an anti-estrogen drug, could contribute to development of future targeted therapies, are important. These findings are published in the May 16, 2014 edition of the journal PLOS ONE....

2014-05-09 16:24:39

LA JOLLA, Calif., May 9, 2014 /PRNewswire/ -- Regulus Therapeutics Inc. (NASDAQ: RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, today announced that Neil W. Gibson, Ph.D., Chief Scientific Officer of Regulus, will present a company overview at the Bank of America Merrill Lynch 2014 Healthcare Conference on Thursday, May 15, 2014 at 12:00 p.m. PDT. The conference is being held at the Encore at the Wynn Las Vegas....

2014-05-08 16:27:14

- 'Clinical Map Initiative' On Track; Advanced RG-101 and RG-012, Expect to Nominate Third microRNA Clinical Candidate by YE 2014 - LA JOLLA, Calif., May 8, 2014 /PRNewswire/ -- Regulus Therapeutics Inc. (NASDAQ:RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, today reported financial results and highlights for the quarter ended March 31, 2014 and provided a summary of recent corporate highlights. "In the first quarter of...

2014-05-01 16:32:43

LA JOLLA, Calif., May 1, 2014 /PRNewswire/ -- Regulus Therapeutics Inc. (NASDAQ:RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, today announced that it will report financial results and highlights for the quarter ended March 31, 2014 on Thursday, May 8, 2014, after the U.S. financial markets close. Regulus will host a conference call and webcast on Thursday, May 8, 2014, at 5:00 pm Eastern Daylight Time to discuss...

2014-04-30 16:30:42

LA JOLLA, Calif., April 30, 2014 /PRNewswire/ -- Regulus Therapeutics Inc. (NASDAQ:RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, today announced that Kleanthis G. Xanthopoulos, Ph.D., President and Chief Executive Officer of Regulus, will present a company overview at the Deutsche Bank 39(th) Annual Healthcare Conference on Wednesday, May 7, 2014 at 8:40 a.m. EDT. The conference is being held at The...


Word of the Day
cenobite
  • One of a religious order living in a convent or in community; a monk: opposed to anchoret or hermit (one who lives in solitude).
  • A social bee.
This word comes from the Latin 'coenobium,' convent, which comes from the Greek 'koinobios,' living in community.
Related